CCS
NBIX icon

Crosspoint Capital Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Crosspoint Capital Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-134
Closed -$5K – 639
2015
Q1 		$5K Buy
+134
New +$4.79K ﹤0.01% 457

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crosspoint Capital Strategies's NBIX Position: Q2 2015 in Review

Crosspoint Capital Strategies sold out of Neurocrine Biosciences (NBIX) in Q2 2015, closing a stake of 134 shares — an estimated $5K sold.

Crosspoint Capital Strategies first reported a position in NBIX in Q1 2015 and held it in 1 quarter. The position peaked at $5K in Q1 2015. 198 funds tracked by Wall St. Rank hold NBIX as of Q2 2015.

  • Crosspoint Capital Strategies reported no remaining Neurocrine Biosciences position as of Q2 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 134 Neurocrine Biosciences shares in Q2 2015, an estimated $5K.
  • Crosspoint Capital Strategies first reported a position in Neurocrine Biosciences in Q1 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Neurocrine Biosciences position peaked at $5K in Q1 2015.
  • 198 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q2 2015, filed 24 Aug 2015.